$CRDF
Cardiff Oncology, Inc.

2021 Q4 Form 10-Q Financial Statement

#000162828021021747 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $133.0K $86.00K $120.0K
YoY Change 10.83% -36.76% 33.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.835M $2.930M $3.420M
YoY Change 12.13% 78.22% 125.0%
% of Gross Profit
Research & Development $5.824M $4.154M $3.200M
YoY Change 82.0% 45.5% 11.89%
% of Gross Profit
Depreciation & Amortization $113.0K $110.0K $120.0K
YoY Change -5.83% -8.33% -66.67%
% of Gross Profit
Operating Expenses $9.659M $7.084M $6.620M
YoY Change 45.91% 57.46% 51.14%
Operating Profit -$6.998M
YoY Change 60.39%
Interest Expense $84.00K $82.00K -$70.00K
YoY Change -220.0% -163.08% -240.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $3.000K -$30.00K
YoY Change -100.0% -150.0%
Pretax Income -$9.442M -$6.913M -$6.600M
YoY Change 43.06% 53.62% 55.66%
Income Tax
% Of Pretax Income
Net Earnings -$9.442M -$6.913M -$6.600M
YoY Change 43.06% 53.72% 55.66%
Net Earnings / Revenue -7099.25% -8038.37% -5500.0%
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$232.5K -$0.17 -$185.0K
COMMON SHARES
Basic Shares Outstanding 39.55M shares 39.55M shares 35.32M shares
Diluted Shares Outstanding 39.55M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $107.5M $134.0M $131.0M
YoY Change -17.92% 268.26% 1184.31%
Cash & Equivalents $11.94M $13.17M $131.0M
Short-Term Investments $95.58M $120.9M
Other Short-Term Assets $4.771M $3.327M $2.100M
YoY Change 127.19% 107.94% 110.0%
Inventory
Prepaid Expenses $4.771M $3.327M $2.055M
Receivables $535.0K $395.0K $320.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $146.1M $137.8M $133.4M
YoY Change 9.58% 260.76% 1074.56%
LONG-TERM ASSETS
Property, Plant & Equipment $382.0K $383.0K $624.0K
YoY Change -38.78% -43.91% -28.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $239.0K $143.0K $404.0K
YoY Change -40.84% -8.2% 156.38%
Total Long-Term Assets $3.417M $3.543M $1.371M
YoY Change 149.23% 180.79% -20.88%
TOTAL ASSETS
Total Short-Term Assets $146.1M $137.8M $133.4M
Total Long-Term Assets $3.417M $3.543M $1.371M
Total Assets $149.5M $141.3M $134.7M
YoY Change 11.0% 258.2% 929.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.439M $396.0K $1.366M
YoY Change 5.34% -35.11% 108.14%
Accrued Expenses $4.527M $4.010M $3.851M
YoY Change 17.55% 10.07% 18.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.559M $5.042M $6.119M
YoY Change 7.19% -7.35% 27.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $30.00K $156.0K
YoY Change -100.0% -66.08% 21.53%
Total Long-Term Liabilities $0.00 $30.00K $156.0K
YoY Change -100.0% -66.08% 21.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.559M $5.042M $6.119M
Total Long-Term Liabilities $0.00 $30.00K $156.0K
Total Liabilities $9.127M $7.768M $6.569M
YoY Change 38.94% 31.04% 13.74%
SHAREHOLDERS EQUITY
Retained Earnings -$259.8M -$250.4M -$231.5M
YoY Change 12.23% 11.33% 10.82%
Common Stock $4.000K $4.000K $4.000K
YoY Change 0.0% -60.32% -51.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $140.4M $133.5M $128.2M
YoY Change
Total Liabilities & Shareholders Equity $149.5M $141.3M $134.7M
YoY Change 11.0% 258.2% 929.51%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$9.442M -$6.913M -$6.600M
YoY Change 43.06% 53.72% 55.66%
Depreciation, Depletion And Amortization $113.0K $110.0K $120.0K
YoY Change -5.83% -8.33% -66.67%
Cash From Operating Activities -$7.390M -$5.465M -$5.120M
YoY Change 44.34% 55.26% 56.1%
INVESTING ACTIVITIES
Capital Expenditures -$107.0K -$98.00K -$60.00K
YoY Change 78.33% -34.67%
Acquisitions
YoY Change
Other Investing Activities -$8.687M $8.147M
YoY Change
Cash From Investing Activities -$8.794M $8.049M -$60.00K
YoY Change 14556.67% -5466.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.96M 0.000 99.76M
YoY Change -85.0% -100.0% 2146.85%
NET CHANGE
Cash From Operating Activities -7.390M -5.465M -5.120M
Cash From Investing Activities -8.794M 8.049M -60.00K
Cash From Financing Activities 14.96M 0.000 99.76M
Net Change In Cash -1.222M 2.584M 94.58M
YoY Change -101.29% -70.13% 8053.45%
FREE CASH FLOW
Cash From Operating Activities -$7.390M -$5.465M -$5.120M
Capital Expenditures -$107.0K -$98.00K -$60.00K
Free Cash Flow -$7.283M -$5.367M -$5.060M
YoY Change 43.93% 59.26% 54.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001213037
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-231495000 USD
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35558
dei Entity Registrant Name
EntityRegistrantName
CARDIFF ONCOLOGY, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2004382
dei Entity Address Address Line1
EntityAddressAddressLine1
11055 Flintkote Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
952-7570
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CRDF
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
120882000 USD
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39552129 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13165000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
130981000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
395000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
320000 USD
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3327000 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2055000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
137769000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
133356000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
383000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
624000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3017000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
343000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
143000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
404000 USD
CY2021Q3 us-gaap Assets
Assets
141312000 USD
CY2020Q4 us-gaap Assets
Assets
134727000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
396000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1366000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4010000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3851000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
594000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
860000 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
42000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
42000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5042000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6119000 USD
CY2021Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5000 USD
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
285000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2691000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
30000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
156000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
7768000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
6569000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
1000 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
1000 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39552000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39552000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36781000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36781000 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
384551000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
361819000 USD
CY2021Q3 crdf Service Receivable
ServiceReceivable
666000 USD
CY2020Q4 crdf Service Receivable
ServiceReceivable
2171000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
16000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250362000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
226000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
247000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
133544000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
128158000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
141312000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
134727000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
86000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
136000 USD
CY2021Q3 us-gaap Revenues
Revenues
86000 USD
CY2020Q3 us-gaap Revenues
Revenues
136000 USD
us-gaap Revenues
Revenues
226000 USD
us-gaap Revenues
Revenues
247000 USD
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4154000 USD
CY2020Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2855000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11552000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8036000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2930000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1644000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8003000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4800000 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
7084000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
4499000 USD
us-gaap Operating Expenses
OperatingExpenses
19555000 USD
us-gaap Operating Expenses
OperatingExpenses
12836000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6998000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4363000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-19329000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12589000 USD
CY2021Q3 us-gaap Interest Income Operating
InterestIncomeOperating
70000 USD
CY2020Q3 us-gaap Interest Income Operating
InterestIncomeOperating
16000 USD
us-gaap Interest Income Operating
InterestIncomeOperating
185000 USD
us-gaap Interest Income Operating
InterestIncomeOperating
67000 USD
CY2021Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 USD
CY2020Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
18000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
18000 USD
CY2021Q3 crdf Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-6893000 USD
CY2020Q3 crdf Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-4503000 USD
CY2021Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
12000 USD
CY2020Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-144000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
280000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-186000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6913000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4497000 USD
us-gaap Net Income Loss
NetIncomeLoss
-18849000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12710000 USD
CY2021Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 USD
CY2020Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
18000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
18000 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6919000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4503000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18867000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15995000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39552000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39552000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23341000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23341000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38501000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38501000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15942000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15942000 shares
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6913000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4497000 USD
us-gaap Net Income Loss
NetIncomeLoss
-18849000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12710000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
26000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
16000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6887000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4497000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18833000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12710000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
282000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5179000 USD
crdf Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-18851000 USD
crdf Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-15995000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
128158000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
268000 USD
CY2021Q1 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1263000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-67000 USD
CY2021Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 USD
CY2021Q1 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
380000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
124817000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1036000 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19225000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
57000 USD
CY2021Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 USD
CY2021Q2 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
546000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6757000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
138918000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
940000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
26000 USD
CY2021Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 USD
CY2021Q3 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
579000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6913000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
133544000 USD
CY2021Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
800000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7310000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
177000 USD
CY2020Q1 crdf Sale Of Stock Value Common And Warrants Net
SaleOfStockValueCommonAndWarrantsNet
-1000000 USD
CY2020Q1 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1456000 USD
CY2020Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 USD
CY2020Q1 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
293000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4089000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
6141000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-8000 USD
CY2020Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
17279000 USD
CY2020Q2 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
4605000 USD
CY2020Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 USD
CY2020Q2 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
213000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4124000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
24382000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
362000 USD
CY2020Q3 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
12911000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000 USD
CY2020Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 USD
CY2020Q3 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
362000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4497000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
33521000 USD
CY2020Q2 crdf Cost Of Issuance Of Common Stock Preferred Stock And Warrants For Clinical Trial Funding Commitment
CostOfIssuanceOfCommonStockPreferredStockAndWarrantsForClinicalTrialFundingCommitment
600000 USD
CY2020Q2 crdf Warrants Fair Value
WarrantsFairValue
400000 USD
us-gaap Net Income Loss
NetIncomeLoss
-18849000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12710000 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1000 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0 USD
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
34000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
338000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
349000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2244000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
821000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1160000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
280000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-186000 USD
crdf Release Of Clinical Trial Funding Commitment For Services Received
ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
1505000 USD
crdf Release Of Clinical Trial Funding Commitment For Services Received
ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
868000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-261000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
74000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
741000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
624000 USD
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-386000 USD
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-240000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-830000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
320000 USD
crdf Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-645000 USD
crdf Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-636000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-126000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-40000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15650000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11191000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
98000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
154000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
15101000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
776000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
146632000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8975000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122654000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-154000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
634000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19225000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18279000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-8000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1263000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
18972000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
305000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20488000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37555000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-117816000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
26210000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130981000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10195000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13165000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36405000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
crdf Preferred Stock Dividend Accrued
PreferredStockDividendAccrued
18000 USD
crdf Preferred Stock Dividend Accrued
PreferredStockDividendAccrued
18000 USD
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
134000000 USD
crdf Lessor Area Of Sublease
LessorAreaOfSublease
16600 sqft
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10742475 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12844384 shares
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
120866000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
25000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
120882000 USD
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3712000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3628000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3329000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3004000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
383000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
624000 USD
crdf Lessee Operating Lease Area Of Lease
LesseeOperatingLeaseAreaOfLease
26100 sqft
crdf Lessor Number Of Subleases
LessorNumberOfSubleases
3 lease
crdf Lessee Operating Lease Area Of Lease Occupied By Company
LesseeOperatingLeaseAreaOfLeaseOccupiedByCompany
9500 sqft
crdf Lessee Operating Lease Monthly Rent Payment
LesseeOperatingLeaseMonthlyRentPayment
80000 USD
crdf Lessor Number Of Subleases
LessorNumberOfSubleases
3 lease
crdf Lessor Area Of Sublease
LessorAreaOfSublease
16600 sqft
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
281000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
99000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
468000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
345000 USD
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
101000 USD
CY2020Q3 us-gaap Sublease Income
SubleaseIncome
73000 USD
us-gaap Sublease Income
SubleaseIncome
303000 USD
us-gaap Sublease Income
SubleaseIncome
218000 USD
CY2021Q3 us-gaap Lease Cost
LeaseCost
180000 USD
CY2020Q3 us-gaap Lease Cost
LeaseCost
26000 USD
us-gaap Lease Cost
LeaseCost
165000 USD
us-gaap Lease Cost
LeaseCost
127000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3017000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
343000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
594000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
860000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2691000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3285000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
869000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y3M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
243000 USD
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
237000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
726000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
706000 USD
CY2021Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3061000 USD
CY2020Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3061000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
163000 USD
CY2021Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
101000 USD
CY2021Q3 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear
62000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
610000 USD
CY2021Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
0 USD
CY2021Q3 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year One
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne
610000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
737000 USD
CY2021Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
0 USD
CY2021Q3 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Two
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo
737000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
754000 USD
CY2021Q3 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
0 USD
CY2021Q3 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Three
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree
754000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
775000 USD
CY2021Q3 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
0 USD
CY2021Q3 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Four
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour
775000 USD
CY2021Q3 crdf Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
933000 USD
CY2021Q3 crdf Lessor Operating Lease Payment To Be Received After Year Four
LessorOperatingLeasePaymentToBeReceivedAfterYearFour
0 USD
CY2021Q3 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueAfterYearFour
933000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3972000 USD
CY2021Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
101000 USD
CY2021Q3 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue
3871000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
687000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3285000 USD
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
940000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
362000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2244000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
821000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1200000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
800000 USD
CY2021Q3 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
5.80
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3150000 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5260992 shares
CY2020Q4 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
5.19
crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P4Y1M6D
crdf Class Of Warrant Or Right Number Exercised
ClassOfWarrantOrRightNumberExercised
770833 shares
crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
1.64
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4490159 shares
crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P3Y2M12D

Files In Submission

Name View Source Status
0001628280-21-021747-index-headers.html Edgar Link pending
0001628280-21-021747-index.html Edgar Link pending
0001628280-21-021747.txt Edgar Link pending
0001628280-21-021747-xbrl.zip Edgar Link pending
crdf-093021exhibit311.htm Edgar Link pending
crdf-093021exhibit312.htm Edgar Link pending
crdf-093021exhibit321.htm Edgar Link pending
crdf-093021exhibit322.htm Edgar Link pending
crdf-20210930.htm Edgar Link pending
crdf-20210930.xsd Edgar Link pending
crdf-20210930_cal.xml Edgar Link unprocessable
crdf-20210930_def.xml Edgar Link unprocessable
crdf-20210930_htm.xml Edgar Link completed
crdf-20210930_lab.xml Edgar Link unprocessable
crdf-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending